Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RH5.2 virus-like particle
- Development stage
- Phase 1
- Lead developer
- University of Oxford
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RH5.2 virus-like particle is a second-generation blood-stage malaria vaccine candidate developed by the University of Oxford. It targets the *Plasmodium falciparum* Reticulocyte-binding protein Homologue 5 (RH5), a highly conserved protein essential for the parasite's invasion of human red blood cells. Unlike the first-generation RH5.1 protein vaccine, RH5.2 is displayed on a virus-like particle (VLP) platform, typically using the SpyTag/SpyCatcher conjugation system on AP205 VLPs. This multivalent display enhances the immunogenicity of the RH5 antigen, aiming to elicit high titers of neutralizing antibodies that block the interaction between RH5 and its erythrocyte receptor, Basigin (CD147), thereby preventing malaria infection and clinical disease.
- Other names
- RH5.2 VLP malaria vaccineRH-5.2 VLP malaria vaccineRH 5.2 VLP malaria vaccine
02
Targets
PfRH5
Beyond the preview
Go deeper on RH5.2 virus-like particle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RH5.2 virus-like particle.